Brainsway (BWAY): which funds own it
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Sections with a free account
No concentrated manager holds it.
Who owns Brainsway?
Brainsway trades in the U.S. through ADRs, certificates that represent shares of a non-U.S. company. Form 13F counts ADRs while the company reports ordinary shares, so we do not compute percentages. Holders reporting more than 5% of the ordinary shares to the SEC (Schedules 13D/13G): Jonathan Shulkin, 19.0% (13D/A filed Jul 1, 2025), Jonathan Shulkin, 15.0% (13D/A filed Oct 8, 2025), Harel Insurance Investments & Financial Services, 8.3% (13G/A filed Jul 29, 2026) and Meitav Investment House, 6.3% (13G/A filed Jun 3, 2026). As of Jun 30, 2026, the largest ADR holders reported on Form 13F were Valor Management (5.3 million ADRs), Masters Capital Management (1.5 million ADRs) and Acadian Asset Management (807,931 ADRs).
Which institutions hold the most Brainsway shares?
Per Form 13F filings as of Jun 30, 2026, in ADRs:
- 1. Valor Management: 5.3 million ADRs
- 2. Masters Capital Management: 1.5 million ADRs
- 3. Acadian Asset Management: 807,931 ADRs
- 4. Essex Investment Management: 592,606 ADRs
- 5. Renaissance Technologies: 475,920 ADRs
- 6. Cresset Asset Management: 314,924 ADRs
- 7. Y.D. More Investments: 237,433 ADRs
- 8. Legato Capital Management: 197,635 ADRs
- 9. Morgan Stanley: 188,968 ADRs
- 10. Eagle Global Advisors: 182,606 ADRs
Sources:13D/A by Jonathan Shulkin (Jul 1, 2025) ↗13D/A by Jonathan Shulkin (Oct 8, 2025) ↗13G/A by Harel Insurance Investments & Financial Services (Jul 29, 2026) ↗13G/A by Meitav Investment House (Jun 3, 2026) ↗All of the company's proxy statements on EDGAR ↗
We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.
Brainsway revenue
Brainsway reported annual revenue of $41.0 million for fiscal year 2024 (year ended December 31, 2024), according to its Form 20-F filed with the SEC (XBRL data).
Quarter flow (concentrated managers)
Concentrated managers holding it
None in the latest quarter.
Largest holders of BWAY (all 13F filers)
- Valor Management5.3 MPrivate equity or venture capital0
- Masters Capital Management1.5 MType not verified−150 K
- Acadian Asset Management808 KQuant or multi-manager−10 K
- Essex Investment Management593 KType not verified−26 K
- Renaissance Technologies476 KQuant or multi-manager−43 K
- Cresset Asset Management315 KWealth adviser0
- Y.D. More Investments237 KType not verified−35 K
- Legato Capital Management198 KType not verified+5,485
- Morgan Stanley189 KBank or trading desk+85 K
- Eagle Global Advisors183 KType not verified+10 K
- Shares
- 5.3 M
- Change
- 0
See more
- Type
- Private equity or venture capital
- Value
- $82.4M
- Masters Capital Management
- Shares
- 1.5 M
- Change
- −150 K
See more
- Type
- Type not verified
- Value
- $23.3M
- Shares
- 808 K
- Change
- −10 K
See more
- Type
- Quant or multi-manager
- Value
- $12.5M
- Essex Investment Management
- Shares
- 593 K
- Change
- −26 K
See more
- Type
- Type not verified
- Value
- $9.2M
- Shares
- 476 K
- Change
- −43 K
See more
- Type
- Quant or multi-manager
- Value
- $7.4M
- Shares
- 315 K
- Change
- 0
See more
- Type
- Wealth adviser
- Value
- $4.9M
- Shares
- 237 K
- Change
- −35 K
See more
- Type
- Type not verified
- Value
- $3.7M
- Shares
- 198 K
- Change
- +5,485
See more
- Type
- Type not verified
- Value
- $3.1M
- Shares
- 189 K
- Change
- +85 K
See more
- Type
- Bank or trading desk
- Value
- $2.9M
- Shares
- 183 K
- Change
- +10 K
See more
- Type
- Type not verified
- Value
- $2.8M
The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.
Insiders (Form 4)
Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.
Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →
Above 5% (13D/13G)
Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.
This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.
- Harel Insurance Investments & Financial Services8.3%13G · amendmentfiling ↗Event: Jun 30, 2026 · filed: Jul 29, 2026
- Meitav Investment House6.31%13G · amendmentfiling ↗Event: Jun 1, 2026 · filed: Jun 3, 2026
- Masters Capital Management3.8%(fell below 5%)13G · amendmentfiling ↗Event: Mar 31, 2026 · filed: May 13, 2026
Above 5% over time (13D/13G)
Each holder with its filings in order. History since December 2024.
This company filed no 8-K forms in the last year. Foreign companies listed in the US (ADRs) report material events on forms 6-K and 20-F, and ETFs and funds do not file 8-Ks. If it is a foreign company listed in the US through ADRs (American Depositary Receipts), what trades are bank-issued certificates that represent shares from its home market. See its filings on EDGAR ↗
Other Health Care stocks in managers' portfolios
Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.
- Agios PharmaceuticalsAGIO · 4 managers
- DavitaDVA · 4 managers
- KardiganKARD · 4 managers
- MapLight TherapeuticsMPLT · 4 managers
- Anteris Technologies GlobalAVR · 5 managers
- Compass TherapeuticsCMPX · 5 managers